During the three months ended March 31, 2022 and 2021, NMM earned approximately $6.3 million and $4.5 million, respectively, in management fees from LMA, which is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA’s IPA line of business (see Note 5 — “Investments in Other Entities — Equity Method”).

During the three months ended March 31, 2022 and 2021, APC paid approximately $0.7 million and $0.5 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5 — “Investments in Other Entities — Equity Method”).

During the three months ended March 31, 2022 and 2021, APC paid approximately $0 and $1.6 million, respectively, to DMG for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC. In October 2021, DMG was consolidated by Apollo. As such, DMG is no longer a related party.

During the three months ended March 31, 2022 and 2021, APC paid approximately $39,000 and $22,000, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.

During the three months ended March 31, 2022 and 2021, APC paid approximately $5,800 and $33,000, respectively, to Fresenius Medical Care (“Fresenius”) and its subsidiaries for services as a provider. During the three months ended March 31, 2022 and 2021, APAACO paid approximately $0.1 million and $0.2 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company’s board members is an officer of Fresenius and its subsidiaries.

During the three months ended March 31, 2022 and 2021, APC paid approximately $0.1 million and $21,000, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company’s board members is a board member of Fulgent Genetics, Inc.

During the three months ended March 31, 2022 and 2021, APC paid an aggregate of approximately $9.3 million and $7.4 million to shareholders, respectively, which included approximately $1.9 million and $1.7 million, respectively, to shareholders who are also officers of APC.

For the three months ended March 31, 2022 and 2021, SCHC paid approximately $0.1 million and $0.1 million, respectively, to Numen, LLC (“Numen”) for an office lease. Numen is owned by a shareholder of APC.

During the three months ended March 31, 2022 and 2021, NMM paid approximately $0.4 million and $0.4 million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 5 — “Investments in Other Entities — Equity Method”).

During the three months ended March 31, 2022 and 2021, APC paid approximately $3.5 million and $0, respectively, to Arroyo Vista Family Health Center (“Arroyo Vista”) for services as a provider. The CEO of Arroyo Vista became a board member with the Company in 2021.

The Company has agreements with Health Source MSO Inc., a California corporation (“HSMSO”), Aurion Corporation (“Aurion”), and AHMC Healthcare Inc. (“AHMC”) for services provided to the Company. One of the Company’s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company’s board members. The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):


	Three Months Ended March 31,
	2022		2021
AHMC – Risk pool, capitation, claims payment	$	11,366	$	13,097
HSMSO – Management fees, net	(80)		(77)
Aurion – Management fees	(75)		(75)

Receipts, net	$	11,211	$	12,945

The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three months ended March 31, 2022 and 2021, the Company has recognized risk pool revenue under this agreement of $12.0 million and $16.9 million, respectively, of which $66.0 million and $58.4 million remained outstanding as of March 31, 2022 and December 31, 2021, respectively.

During the three months ended March 31, 2022 and 2021, NMM paid approximately $0 and $44,000, respectively, to an ApolloMed board member for consulting services.

In addition, affiliates wholly owned by the Company’s officers, including Dr. Thomas Lam, ApolloMed’s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company’s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company’s subsidiaries as related-party transactions.

For equity method investments and loans receivable from related parties, see Notes 5 and 6, respectively.